Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer.
- Published in:
- OncoImmunology, 2015, v. 4, n. 1, p. N.PAG, doi. 10.4161/21624011.2014.955704
- By:
- Publication type:
- Article
Works matching DE "LUNG cancer treatment"
Results: 3152
1
2
Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.
- Published in:
- OncoImmunology, 2014, v. 3, n. 11, p. N.PAG, doi. 10.4161/21624011.2014.970032
- By:
- Publication type:
- Article
3
The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.
- Published in:
- OncoImmunology, 2014, v. 3, n. 11, p. N.PAG, doi. 10.4161/21624011.2014.967142
- By:
- Publication type:
- Article
4
Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses.
- Published in:
- OncoImmunology, 2014, v. 3, n. 6, p. N.PAG, doi. 10.4161/onci.28976
- By:
- Publication type:
- Article
5
The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer.
- Published in:
- OncoImmunology, 2014, v. 3, n. 1, p. N.PAG, doi. 10.4161/onci.27401
- By:
- Publication type:
- Article
6
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.
- Published in:
- OncoImmunology, 2013, v. 2, n. 3, p. e23428-1, doi. 10.4161/onci.23428
- By:
- Publication type:
- Article
7
Victories and deceptions in tumor immunology Stimuvax®.
- Published in:
- OncoImmunology, 2013, v. 2, n. 1, p. e23687-1, doi. 10.4161/onci.23687
- By:
- Publication type:
- Article
8
The associations of nucleotide polymorphisms in mir-196a2, mir-146a, mir-149 with lung cancer risk.
- Published in:
- Cancer Biomarkers, 2015, v. 15, n. 1, p. 57, doi. 10.3233/CBM-140433
- By:
- Publication type:
- Article
9
Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
- Published in:
- Cancer Biomarkers, 2014, v. 14, n. 4, p. 259, doi. 10.3233/CBM-140404
- By:
- Publication type:
- Article
10
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
- Published in:
- Cancer Biomarkers, 2013, v. 13, n. 6, p. 433, doi. 10.3233/CBM-130381
- By:
- Publication type:
- Article
11
Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma.
- Published in:
- Cancer Biomarkers, 2012, v. 10, n. 3/4, p. 145, doi. 10.3233/CBM-2012-0239
- By:
- Publication type:
- Article
12
Lung Cancer in the Elderly: What's Age Got to Do With It?
- Published in:
- Oncology (08909091), 2010, v. 24, n. 12, p. 1120
- By:
- Publication type:
- Article
13
Youth Has No Age: Cancer Treatment for Older Americans.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 12, p. 1114
- By:
- Publication type:
- Article
14
Lung Cancer After 70: Is it a Different Disease?
- Published in:
- Oncology (08909091), 2010, v. 24, n. 12, p. 1106
- By:
- Publication type:
- Article
15
Personalized Medicine for Non-Small-Cell Lung Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 5, p. 399
- By:
- Publication type:
- Article
16
Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCL.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 5, p. 392
- By:
- Publication type:
- Article
17
Managing the Patient With Borderline Resectable Lung Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 3, p. 234
- By:
- Publication type:
- Article
18
Histologic Subtype in NSCLC: Does It Matter?
- Published in:
- Oncology (08909091), 2009, v. 23, n. 13, p. 1133
- By:
- Publication type:
- Article
19
Neoadjuvant Chemotherapy for Resectable Non—Small-Cell Lung Cancer.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 10, p. 879
- By:
- Publication type:
- Article
20
Adjuvant vs Neoadjuvant Chemotherapy in Resectable NSCLC: Is That the Real Question?
- Published in:
- Oncology (08909091), 2009, v. 23, n. 6, p. 534
- By:
- Publication type:
- Article
21
Pemetrexed Receives Third US Approval, as Part of First-Line Regimen for NSCLC.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 11, p. 1248
- Publication type:
- Article
22
High Activity of the Anti-IGF-IR Antibody CP-75 1,871 in Combination With Paclitaxel and Carboplatin in Squamous Non-Small-Cell Lung Cancer.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
23
A Randomized Discontinuation Phase II Study of Sorofenib vs Placebo in Patients With Non-Small-Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens: E2501.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
24
A Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage lilA/B Non-Small- Cell Lung Cancer: A Report of the 2-Year and Median Survival Rates for the RTOG 0324 Trial.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
25
Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Non-Small-Cell Lung Cancer.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
26
Molecular and Clinical Subgroup Analyses From a Phase Ill Trial Comparing Gefitinib With Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (INTEREST).
- Published in:
- 2008
- By:
- Publication type:
- Abstract
27
Acceptable Safety of Bevacizumab Therapy in Patients With Brain Metastases Due to Non-Small-Cell Lung Cancer (PASSPORT).
- Published in:
- 2008
- By:
- Publication type:
- Abstract
28
Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: An Updated Systematic Review and Meta-Analysis.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
29
COMPELLING DATA FOR TOMORROW.
- Published in:
- Oncology (08909091), 2008, p. 24
- By:
- Publication type:
- Article
30
SO 124: A Randomized Phase Ill Trial Comparing Irinotecan/Cisplatin (UP) With Etoposide/Cisplatin (EP) in Patients With Previously Untreated Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
31
PRACTICE-CHANGING IMPLICATIONS TODAY.
- Published in:
- Oncology (08909091), 2008, p. 20
- By:
- Publication type:
- Article
32
FLEX: A Randomized, Multicenter, Phase Ill Study of Cetuximab in Combination With Cisplatin/Vinorelbine (CV) vs CV Alone in the First-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2008
- By:
- Publication type:
- Abstract
33
Cetuximab Plus Platinum-Based Chemotherapy Improves Survival for Patients With Newly Diagnosed Advanced Lung Cancer.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 7, p. 800
- Publication type:
- Article
34
The Role of Surgery in Stage III Non-Small-Cell Lung Cancer.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 5, p. 557
- By:
- Publication type:
- Article
35
Management of a Patient With Stage IIIA (N2) NSCLC.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 5, p. 553
- By:
- Publication type:
- Article
36
Adjuvant Treatment of Stage IB NSCLC.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 5, p. 511
- By:
- Publication type:
- Article
37
PORTable Indications in Non-Small-Cell Lung Carcinoma.`.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
38
Does PORT Have a Role in Lung Cancer?
- Published in:
- 2008
- By:
- Publication type:
- Editorial
39
Postoperative Radiation Therapy for Lung Cancer: Where Do We Stand?
- Published in:
- Oncology (08909091), 2008, v. 22, n. 3, p. 301
- By:
- Publication type:
- Article
40
Limited- Stage Small-Cell Lung Cancer: Therapeutic Options.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 3, p. 303
- By:
- Publication type:
- Article
41
Treating Small-Cell Lung Cancer: More Consensus Than Controversy.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 3, p. 312
- By:
- Publication type:
- Article
42
Advanced Non-Small-Cell Lung Cancer: New Data, Therapy Choices, and Challenging Decisions.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 6, p. 626
- By:
- Publication type:
- Article
43
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
44
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
- Published in:
- 2016
- By:
- Publication type:
- journal article
45
A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer.
- Published in:
- PLoS Medicine, 2006, v. 3, n. 12, p. 2229, doi. 10.1371/journal.pmed.0030467
- By:
- Publication type:
- Article
46
Pontine metastasis as an initial presentation of lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- Case Study
47
Radioresistance of cancer stem-like cell derived from canine tumours.
- Published in:
- Veterinary & Comparative Oncology, 2016, v. 14, n. 3, p. e93, doi. 10.1111/vco.12110
- By:
- Publication type:
- Article
48
Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.
- Published in:
- International Journal of Clinical Oncology, 2012, v. 17, n. 4, p. 395, doi. 10.1007/s10147-011-0304-5
- By:
- Publication type:
- Article
49
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
- Published in:
- International Journal of Clinical Oncology, 2012, v. 17, n. 2, p. 155, doi. 10.1007/s10147-011-0256-9
- By:
- Publication type:
- Article
50
The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2012, v. 17, n. 2, p. 112, doi. 10.1007/s10147-011-0266-7
- By:
- Publication type:
- Article